Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.240
-0.030 (-1.32%)
At close: Apr 28, 2026, 4:00 PM EDT
2.280
+0.040 (1.79%)
After-hours: Apr 28, 2026, 5:56 PM EDT
Fortress Biotech Employees
Fortress Biotech had 78 employees as of December 31, 2025. The number of employees decreased by 23 or -22.77% compared to the previous year.
Employees
78
Change (1Y)
-23
Growth (1Y)
-22.77%
Revenue / Employee
$811,051
Profits / Employee
-$24,128
Market Cap
72.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Filana Therapeutics | 20 |
| MAIA Biotechnology | 13 |
| OS Therapies | 5 |
FBIO News
- 7 days ago - Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ - GlobeNewsWire
- 4 weeks ago - Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 2 months ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 2 months ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 2 months ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire